|
US3274118A
(en)
|
1962-01-22 |
1966-09-20 |
Lithium Corp |
Preparation of stable non-pyrophoric organometallic compositions
|
|
US5721356A
(en)
|
1989-09-15 |
1998-02-24 |
Gensia, Inc. |
Orally active adenosine kinase inhibitors
|
|
US5962473A
(en)
|
1996-08-16 |
1999-10-05 |
Eli Lilly And Company |
Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F
|
|
US6608053B2
(en)
|
2000-04-27 |
2003-08-19 |
Yamanouchi Pharmaceutical Co., Ltd. |
Fused heteroaryl derivatives
|
|
BR0115995A
(pt)
|
2000-12-19 |
2004-01-13 |
Merck Patent Gmbh |
Formulação farmacêutica compreendendo pirazolo[4,3-d]pirimidinas e antitrombóticos, antagonistas de cálcio, prostaglandinas ou derivados de prostaglandina
|
|
US20040235877A1
(en)
|
2001-09-14 |
2004-11-25 |
Natsuki Ishizuka |
Novel use of tricyclic compound
|
|
KR20050058507A
(ko)
|
2002-09-04 |
2005-06-16 |
쉐링 코포레이션 |
사이클린 의존성 키나제 억제제로서의 피라졸로피리미딘
|
|
WO2004026867A2
(en)
|
2002-09-19 |
2004-04-01 |
Schering Corporation |
Imidazopyridines as cyclin dependent kinase inhibitors
|
|
JP4895806B2
(ja)
|
2003-04-09 |
2012-03-14 |
エクセリクシス， インク． |
Ｔｉｅ−２モジュレータと使用方法
|
|
TW200536536A
(en)
|
2004-02-25 |
2005-11-16 |
Schering Corp |
Pyrazolotriazines as kinase inhibitors
|
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
|
KR20070118068A
(ko)
|
2004-11-23 |
2007-12-13 |
레디 유에스 테라퓨틱스 인코포레이티드 |
신규의 이원 헤테로고리 화합물, 그 제조방법 및 이들을포함하는 조성물
|
|
JP5238936B2
(ja)
|
2005-03-25 |
2013-07-17 |
ジーアイティーアール，インク． |
Ｇｉｔｒ結合分子およびその使用
|
|
DK1879573T3
(da)
|
2005-05-10 |
2013-02-25 |
Incyte Corp |
Modulatorer af indolamin 2,3-dioxygenase og fremgangsmåder til anvendelse deraf
|
|
KR101704734B1
(ko)
|
2005-07-01 |
2017-02-09 |
이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
|
|
ES2540561T3
(es)
|
2005-12-20 |
2015-07-10 |
Incyte Corporation |
N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
|
|
CL2007002650A1
(es)
|
2006-09-19 |
2008-02-08 |
Incyte Corp |
Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
|
|
CA2663057C
(en)
|
2006-09-19 |
2015-12-08 |
Incyte Corporation |
N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
|
|
US7750007B2
(en)
|
2006-11-06 |
2010-07-06 |
Supergen, Inc. |
Imidazo[1,2-beta]pyridazine and pyrazolo[1,5-alpha]pyrimidine derivatives and their use as protein kinase inhibitors
|
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
|
PT2175884T
(pt)
|
2007-07-12 |
2016-09-21 |
Gitr Inc |
Terapias de combinação empregando moléculas de ligação a gitr
|
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
|
WO2009073620A2
(en)
|
2007-11-30 |
2009-06-11 |
Newlink Genetics |
Ido inhibitors
|
|
EP2229390B1
(en)
|
2007-12-14 |
2014-04-09 |
F. Hoffmann-La Roche AG |
Novel imidazoý1,2-a¨pyridine and imidazoý1,2-b¨pyridazine derivatives
|
|
EP2296789A1
(fr)
|
2008-05-29 |
2011-03-23 |
Saint-Gobain Centre de Recherches et d'Etudes Européen |
Structure en nid d'abeille a base de titanate d'aluminium
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
PE20100362A1
(es)
|
2008-10-30 |
2010-05-27 |
Irm Llc |
Derivados de purina que expanden las celulas madre hematopoyeticas
|
|
MX356367B
(es)
|
2008-12-09 |
2018-05-25 |
Genentech Inc |
Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
|
|
IN2015DN02826A
(enExample)
|
2009-09-03 |
2015-09-11 |
Merck Sharp & Dohme |
|
|
EP2493862B1
(en)
|
2009-10-28 |
2016-10-05 |
Newlink Genetics Corporation |
Imidazole derivatives as ido inhibitors
|
|
PL2509602T3
(pl)
|
2009-12-04 |
2017-08-31 |
Senhwa Biosciences, Inc. |
Pirazolopirymidyny i podobne heterocykle jako inhibitory ck2
|
|
DK2510010T3
(en)
|
2009-12-10 |
2015-12-14 |
Hoffmann La Roche |
Antibodies that bind to human CSF1R extracellular domain 4 and their use
|
|
DK2542256T3
(da)
|
2010-03-04 |
2019-08-26 |
Macrogenics Inc |
Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
|
|
CN102918061B
(zh)
|
2010-03-05 |
2016-06-08 |
霍夫曼-拉罗奇有限公司 |
针对人csf-1r的抗体及其用途
|
|
RU2617971C2
(ru)
|
2010-03-05 |
2017-04-28 |
Ф.Хоффманн-Ля Рош Аг |
Антитела против csf-1r человека и их применение
|
|
EP3943154A1
(en)
|
2010-05-04 |
2022-01-26 |
Five Prime Therapeutics, Inc. |
Antibodies that bind csf1r
|
|
NZ729044A
(en)
|
2010-09-09 |
2020-07-31 |
Pfizer |
4-1bb binding molecules
|
|
WO2012044562A2
(en)
|
2010-09-30 |
2012-04-05 |
Merck Sharp & Dohme Corp. |
Pyrazolopyrimidine pde10 inhibitors
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
GB201103837D0
(en)
|
2011-03-07 |
2011-04-20 |
Oxagen Ltd |
Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
|
|
NO2694640T3
(enExample)
|
2011-04-15 |
2018-03-17 |
|
|
|
CA2833636A1
(en)
|
2011-04-20 |
2012-10-26 |
Amplimmune, Inc. |
Antibodies and other molecules that bind b7-h1 and pd-1
|
|
AU2012244550C1
(en)
|
2011-04-21 |
2017-06-22 |
Origenis Gmbh |
Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors
|
|
BR112014012819B1
(pt)
|
2011-11-28 |
2022-08-16 |
Merck Patent Gmbh |
Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
|
|
WO2013086436A1
(en)
|
2011-12-08 |
2013-06-13 |
Fred Hutchinson Cancer Research Center |
Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
|
|
MX356337B
(es)
|
2011-12-15 |
2018-05-23 |
Hoffmann La Roche |
Anticuerpos contra csf-1r humano y sus usos.
|
|
MX2014008961A
(es)
|
2012-02-06 |
2014-10-14 |
Genentech Inc |
Composiciones y metodos para utilizar inhibidores de csf1r.
|
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
|
AR090650A1
(es)
|
2012-04-12 |
2014-11-26 |
Alcon Res Ltd |
Tratamiento para respuestas inflamatorias inducidas por microbios en el ojo
|
|
KR20150018533A
(ko)
|
2012-05-11 |
2015-02-23 |
파이브 프라임 테라퓨틱스, 인크. |
콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
|
|
AR091649A1
(es)
|
2012-07-02 |
2015-02-18 |
Bristol Myers Squibb Co |
Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
|
|
CN107759690A
(zh)
|
2012-08-31 |
2018-03-06 |
戊瑞治疗有限公司 |
用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
|
|
WO2014060112A1
(en)
|
2012-10-19 |
2014-04-24 |
Origenis Gmbh |
Pyrazolo[4,3-d]pyrimidines as kinase inhibitors
|
|
WO2014138485A1
(en)
|
2013-03-08 |
2014-09-12 |
Irm Llc |
Ex vivo production of platelets from hematopoietic stem cells and the product thereof
|
|
US11427600B2
(en)
*
|
2014-06-27 |
2022-08-30 |
Nogra Pharma Limited |
Aryl receptor modulators and methods of making and using the same
|
|
CN108290855A
(zh)
|
2015-07-01 |
2018-07-17 |
西北大学 |
被取代的喹唑啉化合物及其调节葡糖脑苷脂酶活性的用途
|
|
US20180072741A1
(en)
|
2016-09-09 |
2018-03-15 |
Incyte Corporation |
Pyrazolopyrimidine compounds and uses thereof
|
|
US10457683B2
(en)
|
2017-04-12 |
2019-10-29 |
Magenta Therapeutics Inc. |
Aryl hydrocarbon receptor antagonists and uses thereof
|
|
MX2019012431A
(es)
|
2017-04-21 |
2020-08-03 |
Ikena Oncology Inc |
Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
|
|
KR20210110566A
(ko)
|
2018-10-16 |
2021-09-08 |
이케나 온콜로지, 인코포레이티드 |
인돌 ahr 저해제 및 이의 용도
|
|
EP4065090A1
(en)
|
2019-11-26 |
2022-10-05 |
Ikena Oncology, Inc. |
Ahr inhibitors and uses thereof
|
|
AU2020394424A1
(en)
|
2019-11-26 |
2022-06-16 |
Ikena Oncology, Inc. |
Polymorphic carbazole derivatives and uses thereof
|
|
BR112022013673A2
(pt)
|
2020-01-10 |
2022-09-13 |
Ikena Oncology Inc |
Inibidores de ahr e seus usos
|
|
CA3196535A1
(en)
|
2020-10-28 |
2022-05-05 |
Alfredo C. Castro |
Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine
|